Dilzene

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dilzene

Property Description
Active ingredient Diltiazem hydrochloride
Form Tablet, Extended-release Capsule, Injectable solution
Pharmacological class Non-dihydropyridine Calcium Channel Blocker (CCB)
General Purpose Anti-hypertensive, Anti-anginal, Antiarrhythmic support
Origin Synthetic Benzothiazepine derivative

What Type of Cardiovascular Medicine is Dilzene?

Dilzene is a prescription medicine for the cardiovascular system whose active component is Diltiazem hydrochloride, a synthetic compound. This single-entity product is classified chemically as a Benzothiazepine derivative and pharmacologically as a non-dihydropyridine calcium channel blocker (CCB). This CCB influences the heart's electrical conduction system, which is a key distinguishing factor. It is also classified as a Class IV antiarrhythmic agent, signifying its use in regulating heart rhythm.

Composition and General Purpose of Diltiazem

The core of the medicine's composition is Diltiazem hydrochloride, which is formulated with basic excipients for solid forms or a sterile aqueous vehicle for liquid preparations. The drug's mechanism involves acting as a calcium ion cellular influx inhibitor, or "slow channel blocker." By modulating the influx of calcium, the medicine induces coronary vasodilation and peripheral vasodilation, simultaneously relaxing arterial muscle and decreasing vascular resistance. This pharmacological action modulates the heart’s electrical system and promotes coronary artery dilation, providing overall anti-hypertensive effects and anti-anginal relief. A typical use scenario involves the long-term management of high blood pressure or chronic stable angina.

Available Pharmaceutical Forms of Dilzene

Diltiazem, available under the brand Dilzene and others, is supplied in several distinct dosage forms intended for systemic circulation. These preparations are differentiated by their release profiles, including standard, immediate-release tablets and specialized extended-release capsules designed for once-daily oral administration. For situations requiring rapid clinical intervention, the drug is also available as an injectable solution, which is administered through the intravenous route of administration. The availability of both immediate-release and extended-release formats represents a key differentiating factor in patient treatment strategy.

Regulatory References

  1. National Institutes of Health (NIH) confirms Diltiazem’s efficacy

What side effects are possible with Dilzene?

Possible Side Effects and Safety Information

The safety profile of Dilzene (Diltiazem hydrochloride) is documented in regulatory labeling by classification of adverse reactions based on their frequency and the physiological systems affected. These classifications establish the risk profile without providing clinical advice or usage instructions.


Frequency and System Classification

Adverse reactions are formally grouped into categories such as Common (e.g., peripheral edema, headache, constipation, fatigue), Uncommon (e.g., bradycardia, palpitations, nausea, dizziness), and Rare (e.g., hypotension, syncope, A-V block), as defined in regulatory documents like the Summary of Product Characteristics (SmPC).

Reactions are primarily reported across several System-Organ Classes (SOCs), most notably Cardiac Disorders (including A-V block and bradycardia), Vascular Disorders (including hypotension), Nervous System Disorders, and Gastrointestinal Disorders.


Serious Adverse Reactions and Safety Constraints

Certain severe reactions are specifically highlighted in official labeling due to their clinical significance. These Serious Adverse Reactions include the development or exacerbation of Congestive Heart Failure, significant Hypotension, and Second or Third-degree Atrioventricular (AV) block. Additionally, rare but severe dermatological events, such as Stevens-Johnson Syndrome, are documented.

Safety constraints, or Contraindications, define absolute safety limits. The medicine should not be used in individuals with Sick Sinus Syndrome or Second or Third-degree AV Block (unless a pacemaker is present), Severe Hypotension, or Cardiogenic Shock.


Population and Time-Related Safety Patterns

Safety notes specify considerations for certain patient groups; for instance, older adults may face an increased risk of side effects like bradycardia. Furthermore, official documents note that effects like Hypotension and changes in hepatic enzymes are often observed more frequently during the treatment initiation phase or following dose escalation.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Dilzene (Diltiazem hydrochloride) is officially documented in regulatory information as potentially leading to severe and life-threatening cardiovascular manifestations.

Documented Overdose Presentations and Severe Outcomes

Acute overdose may present as profound cardiodepression, characterized by severe bradycardia (abnormally slow heart rate), hypotension (severely low blood pressure), and high-grade atrioventricular (AV) blocks. Systemic manifestations can include dizziness, confusion, nausea, and vomiting. Severe outcomes listed in official documents include progression to cardiac failure, shock, cardiac arrest (asystole), and death. Hyperglycaemia is a recognized metabolic complication. The delayed onset of toxicity following ingestion of extended-release formulations is a recognized clinical factor requiring extended observation.

Emergency Actions and Supportive Measures

In the event of a known or suspected overdose, immediate medical attention must be sought. Individuals must call emergency services if the victim has collapsed, is having a seizure, has trouble breathing, or cannot be awakened. Regulatory guidance confirms that management is symptomatic and supportive, as no specific antidote is known. Officially described supportive measures include the use of intravenous calcium and inotropic agents to manage hypotension, and cardiac pacing for fixed high-grade AV block. Continuous ECG monitoring in a hospital setting is mandatory.

Therapeutic Uses of Dilzene

Main Uses and Benefits of Dilzene

Dilzene contains the active substance diltiazem, which belongs to a group of medications known as calcium channel blockers. It is primarily used to manage conditions affecting the cardiovascular system by influencing the movement of calcium into the muscle cells of the heart and blood vessels.

Chronic Stable Angina Pectoris

Dilzene is indicated for the long-term management of chronic stable angina pectoris, a condition characterized by chest pain or discomfort. This pain occurs when the heart muscle does not receive enough oxygen-rich blood, often during physical exertion or stress. The medication helps by:

  • Reducing the workload on the heart muscle.
  • Improving blood flow through the coronary arteries.
  • Decreasing the frequency and severity of angina attacks.

Hypertension (High Blood Pressure)

The medication is also used to treat essential hypertension. By relaxing the walls of the peripheral blood vessels, Dilzene allows blood to flow more easily, which leads to a reduction in systemic blood pressure. Consistent control of blood pressure is a fundamental component in managing cardiovascular health.

Mechanism of Action

The therapeutic benefits of Dilzene are derived from its ability to inhibit the influx of calcium ions during membrane depolarization in cardiac and vascular smooth muscle. This action results in several physiological effects:

  • Vasodilation: It relaxes the smooth muscle in the arterial walls, leading to lower vascular resistance.
  • Heart Rate Regulation: It can slow the electrical conduction through the atrioventricular (AV) node, which may help in stabilizing certain heart rhythms.
  • Reduced Oxygen Demand: By lowering blood pressure and heart rate, the heart requires less oxygen to function effectively.

Regulatory References

  1. Diltiazem: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Regulatory documents establish strict guidelines outlining the specific populations that must not use Dilzene, primarily based on underlying cardiac function and general physiological status.

Populations for Whom Use is Contraindicated

Dilzene is formally contraindicated and must not be used in patients with the following severe conditions:

  • Cardiac Conduction Defects: Patients with Sick Sinus Syndrome or Second- or Third-Degree Atrioventricular (AV) Block, unless they have a permanently functioning ventricular pacemaker in place.
  • Accessory Bypass Tract: Patients experiencing Atrial Fibrillation or Flutter associated with an accessory bypass tract (such as Wolff-Parkinson-White syndrome).
  • Hemodynamic Instability: Patients presenting with Severe Hypotension (systolic blood pressure less than 90 mm Hg) or Cardiogenic Shock.
  • Acute Events: Following an Acute Myocardial Infarction complicated by Pulmonary Congestion.
  • Allergy: A documented Hypersensitivity to the drug.

Special Population Eligibility

  • Pediatric Use: Safety and effectiveness have not been established in the pediatric population.
  • Geriatric Use: Use in the elderly requires caution due to a higher likelihood of age-related organ dysfunction (kidney, liver) which may affect drug clearance.
  • Organ Impairment: Patients with Impaired Hepatic or Renal Function should be monitored closely, and the drug must be used with caution.
  • Pregnancy/Lactation: Use during pregnancy is generally limited to cases where the potential benefit justifies the potential fetal risk, as animal studies have shown potential teratogenic effects. Minimal risk to the infant has been suggested during breastfeeding.

What should I know about interactions with other medicines?

Dilzene's interaction profile is defined by pharmacokinetic and pharmacodynamic constraints formally documented in regulatory labeling. Certain combinations are explicitly contraindicated due to the risk of severe adverse outcomes, and these prohibitions include co-administration with Dantrolene (infusion), Ivabradine, Lomitapide, and Pimozide.

The drug is officially classified as a moderate inhibitor of the CYP3A4 enzyme and a weak inhibitor of P-glycoprotein (P-gp). This metabolic profile leads to a documented increase in the plasma concentrations of many co-administered medicines that are CYP3A4 substrates, such as specific statins (e.g., Simvastatin, Atorvastatin) and antiarrhythmics like Amiodarone. Conversely, strong CYP3A4 inducers like Rifampin or the herbal product St. John's Wort can lead to a documented decrease in Diltiazem exposure.

Pharmacodynamic interactions are also formally documented, particularly with other cardiovascular agents. The co-administration of Diltiazem with beta-blockers or digitalis/digoxin results in additive effects on heart rate and conduction, a pattern explicitly noted in regulatory materials. Furthermore, ingestion-based constraints exist, as Grapefruit Juice may modestly increase Diltiazem's systemic exposure. For certain extended-release formulations, the co-ingestion of Alcohol is restricted due to the potential for a rapid release and increased absorption of the active ingredient, as stated in the prescribing information.

Mechanism of Action

How Dilzene Works

The active component of Dilzene, Diltiazem, functions as a non-dihydropyridine calcium channel inhibitor, applying a dual and balanced mechanism across the cardiovascular system. Its core action is the highly specific blockade of L-type voltage-gated calcium channels on both the heart and the vasculature.


Modulating Cardiac Electrical Conduction

This mechanism covers the drug's effect on the Sinoatrial (SA) and Atrioventricular (AV) nodes, the heart's natural electrical relays. By reducing the calcium ion influx required for the slow inward current, the mechanism produces negative chronotropy (slowing heart rate) and negative dromotropy (slowing AV conduction), which results in a slowing of the spontaneous firing rate and prolongation of the refractory period, causing a net physiological effect of reduced energy requirements for contraction and impulse generation.


Regulating Vascular and Myocardial Muscle Tone

This mechanism targets L-type calcium channels on vascular smooth muscle cells in the coronary and peripheral arteries, as well as the myocardium. Limiting calcium availability interferes with muscle contraction, resulting in coronary vasodilation (widening of heart's blood vessels) and peripheral vasodilation (reduction of systemic resistance). The mechanism of slowing the heart and relaxing the arteries lowers the total resistance and rate the heart must overcome, defining the integrated physiological responses of this drug class.

Dosage and Administration Information

How to Use Dilzene: Administration Guidelines

The use of Dilzene (Diltiazem) is defined by its two primary administration methods and release profiles. For long-term maintenance of chronic cardiovascular conditions, the medicine is taken via the Oral route, using either immediate-release (IR) or various extended-release (ER/LA) forms. For acute, temporary control of rapid heart rhythms in supervised settings, an Intravenous (IV) injection is administered.

Oral Dosing and Scheduling

Oral forms are differentiated by their frequency. The ER/LA forms are typically taken once daily, with maintenance dose ranges for chronic conditions extending up to 540 mg per day. IR tablets require multiple times daily administration, often to be taken before meals and at bedtime to maintain consistent levels. Clinical guidelines suggest that oral dose adjustments must be performed gradually, with intervals of 7 to 14 days, allowing time for the full effect of the previous dose to be realized before any increase.

Administration Constraints and Special Populations

A key procedural constraint for oral use is that all extended-release forms must be swallowed whole and are not to be crushed or chewed, a requirement critical for maintaining the intended release mechanism. IV administration is reserved for acute settings, requiring the bolus dose to be administered slowly, typically over 2 minutes, under continuous cardiac monitoring. Clinical observations indicate that for older adults or patients with hepatic impairment, a lower initial oral dose may be recommended, while use in the pediatric population is not established.

Recent Clinical Evidence

Research evidence / Overview of studies for Dilzene

Evidence from Trials for Essential Hypertension (High Blood Pressure)

Dilzene (Diltiazem) was studied for use in essential hypertension in large-scale Randomized Controlled Trials (RCTs) and comprehensive meta-analyses that reviewed the accumulated evidence. These studies research examined how blood pressure levels changed over time, specifically monitoring Systolic and Diastolic Blood Pressure (SBP/DBP), and tracked the long-term occurrence of specific clinical endpoints such as stroke and heart attack. The trials included adults with varying degrees of high blood pressure.

In the short term, studies reported how symptoms evolved in the observed populations related to measured SBP and DBP compared to initial levels. For long-term follow-up, evidence from comparative trials data show patterns related to outcomes observed with other classes of anti-hypertensive medicines. However, the evidence quality varies across studies when comparing its use against every other class of anti-hypertensive medication. Long-term effects are not fully established when Dilzene is used as the sole treatment (monotherapy) for all patients.

Evidence from Trials for Chronic Stable Angina

For chronic stable angina, research was studied for short-term, placebo-controlled trials and crossover designs. These trials monitored outcomes related to physical discomfort and activity level during standardized exercise testing. The measured endpoints included the total duration of outcomes reflecting daily functioning and the time until the onset of episodic or acute changes in heart activity during the tests.

Studies reported how symptoms evolved in the observed populations regarding the onset of patient-reported discomfort and changes in the heart's electrical activity compared to placebo. A key limitation is that follow-up durations were limited to the short or intermediate term, and the evidence primarily relies on functional measures rather than tracking major long-term clinical outcomes in this patient population.

Evidence for Acute Heart Rate Control in Arrhythmias

Dilzene was evaluated in studies conducted in acute medical settings for its use in conditions involving rapid heartbeats, specifically Atrial Fibrillation or Flutter with a Rapid Ventricular Response (RVR). The primary goal of these trials research examined the time required to achieve a specific heart rate measurement, which was defined as below a certain threshold. The findings describe patterns observed in the studies where the target heart rate measurement was observed within a short time frame (minutes to hours) following administration. The evidence is limited from prospective trials regarding the long-term use of Dilzene in monitoring heart rhythm patterns once the acute phase is over.

Key Studies & References

  1. Diltiazem: MedlinePlus Drug Information
  2. Diltiazem: A clinical review
  3. Initial Diltiazem Dose Is Associated With Significant Hypotension in Patients With Atrial Fibrillation and Rapid Ventricular Rate

Frequently Asked Questions (FAQ)

Common questions about Dilzene (FAQ)

Q: How does Dilzene compare to other calcium channel blockers (CCBs)?

Official pharmacological documents classify Dilzene as a non-dihydropyridine calcium channel blocker (CCB). This type is generally more selective for the heart muscle and electrical system, and its mechanism of action involves negative chronotropy (slowing heart rate). In contrast, other CCBs, known as dihydropyridines, are typically more focused on relaxing blood vessels in the body.

Q: Are there any known long-term side effects associated with continuous Dilzene use?

Regulatory documents note that serious adverse events reported include the development or worsening of conditions like heart failure and heart block. Changes in liver function have also been reported, which may necessitate monitoring. These potential effects are subjects of ongoing safety surveillance.

Q: Can Dilzene be taken alongside common nutritional supplements or vitamins?

Official product information notes a known interaction with the herbal supplement St. John's Wort, which can decrease the amount of Dilzene in the body. For all other vitamins and supplements, official guidance indicates that healthcare professionals are to be informed of all supplements and vitamins being taken.

Q: What other prescription medications should be reported before starting Dilzene?

The drug is classified as a moderate inhibitor of the CYP3A4 enzyme, meaning it can increase the concentration of many co-administered medicines. Prescription medications commonly affected include certain antiarrhythmics, some statin drugs, and strong CYP3A4 inducers. Patients are generally advised to inform their healthcare provider of all prescription medications they are currently taking.

Q: What are the general rules for taking Dilzene with or without food?

For the extended-release capsules, official regulatory information indicates that absorption is not significantly affected when the medication is taken with food. However, official guidelines for immediate-release tablets describe administration multiple times daily, often before meals and at bedtime.

Q: What is the safety classification of Dilzene for use during pregnancy?

Official documents note that use during pregnancy is generally limited to cases where the potential benefit is determined to outweigh the potential fetal risk. Animal studies have shown potential effects on the fetus. When the drug is combined with other medications, it may carry a higher safety risk classification in later stages of pregnancy.

Q: Does Dilzene have a known effect on mental clarity or concentration?

Adverse event reports note effects on the nervous system, including nervousness and somnolence, which is a state of strong desire for sleep. Patients are advised to consider these potential effects as part of their experience with the medication.

Q: Can Dilzene affect a person's ability to drive or operate machinery?

According to official safety information, side effects such as dizziness and somnolence (sleepiness) have been reported. These effects have the potential to impact the ability to perform tasks that require mental alertness, such as driving or operating heavy machinery.

Q: Does Dilzene require any specific blood tests or monitoring while in use?

Regulatory documents state that because the medicine is processed extensively by the liver and excreted by the kidneys, tests monitoring both renal (kidney) and hepatic (liver) function should be performed at regular intervals during prolonged use. This helps monitor for any changes in how the body handles the drug.

Q: Why is Dilzene sometimes chosen instead of other similar medications?

Dilzene's classification as a non-dihydropyridine calcium channel blocker gives it a specific action profile. It has a notable selective influence on the heart's electrical conduction system, which slows the heart rate, in addition to promoting blood vessel relaxation. This dual and balanced mechanism is a key factor in its therapeutic use.

Q: What does the research evidence say about the long-term effectiveness of Dilzene?

Research confirms that statistically significant decreases in blood pressure are observed within the first month of treatment. However, official documents indicate that the long-term effects of Dilzene when used as a single treatment (monotherapy) are not fully established for all patients.

Q: How is Dilzene related to other '-zem' or '-pine' medications?

Dilzene's active component, diltiazem, is sometimes grouped into the '-zem' family of medicines, which are non-dihydropyridine CCBs. Other CCBs, such as those ending in '-pine,' are generally classified as dihydropyridines and exhibit a different physiological focus on the blood vessels.

Q: Is there any known risk of dependency or withdrawal from Dilzene?

According to official regulatory information, Dilzene is not classified as a controlled substance and carries no DEA Schedule classification. The official label does not include warnings typical of drugs associated with dependence or addiction risk.

Q: How long does it typically take for Dilzene to start noticeably working?

Official pharmacokinetic studies show that after a single dose of the extended-release capsule, the active component is detectable in the plasma within approximately two hours. The highest level of concentration in the blood is typically reached between 10 and 14 hours after administration.

Q: Does Dilzene interact with common over-the-counter pain relievers?

The official label does not document major, specific interactions with non-prescription pain relievers like acetaminophen. However, as with all medications, patients are advised to inform their healthcare professional of any over-the-counter pain relievers they use, as additive effects on blood pressure may occur.

Q: What should be done in the event of a missed dose of Dilzene?

The official guidance advises that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Patients should not take extra medicine to compensate for the dose that was missed.

Q: Is there a generic version of Dilzene available?

Yes, the active ingredient in Dilzene, which is diltiazem, has been approved by the FDA as a generic version. These generic formulations are available in the various immediate-release and extended-release formats.

Q: Are there studies examining Dilzene's use in the elderly population?

Research has specifically examined the effectiveness and tolerance of diltiazem in the elderly population for conditions like stable angina. Furthermore, official FDA labeling notes that patients 60 years of age and older may require a lower initial dose.

Q: Does Dilzene interact with common cold, cough, or flu remedies?

Many cold, cough, and flu remedies contain sympathomimetic agents, such as decongestants. General safety warnings indicate that these agents can cause adverse cardiovascular effects. Therefore, they are to be administered cautiously in individuals with underlying cardiovascular disorders.

Q: Can Dilzene affect blood sugar control in people with diabetes?

A controlled clinical study that examined the effects of diltiazem in patients with Type II diabetes reported that the medication did not have a negative effect on diabetes control. This finding was based on measurements of HbA1C and fasting blood glucose levels.

Q: How will I know if Dilzene is actually working for my condition?

For high blood pressure, the effectiveness of the medication is measured by observed decreases in systolic and diastolic blood pressure over time. For conditions like angina, official research endpoints include improvements in a person's exercise tolerance and physical activity level during standardized testing.

Q: What should a patient tell a surgeon or dentist before a procedure?

Regulatory precautions indicate that patients are to inform the surgeon or dentist of all current medications being taken. This is important because Dilzene can intensify the effects of other medications used during anesthesia or surgery that affect blood pressure, heart muscle contraction, or heart electrical conduction.

Q: Can Dilzene cause a lingering cough as a side effect?

Yes, official safety information documents that a cough or increased frequency of coughing has been reported as a common adverse event in clinical trials. This effect is categorized under disorders of the respiratory system.

How should Dilzene be stored and disposed of?

How to Store and Dispose of Dilzene

Dilzene (Diltiazem Hydrochloride) must be stored at Controlled Room Temperature, defined as 20 to 25 C (68 to 77 F), with permitted temperature variations. The medicine must be kept in a light-resistant, tight container and stored in a location that avoids excessive humidity. It is mandatory to Keep out of reach of children and to Do Not Freeze the product.

Stability and Handling

If the contents of the extended-release capsules are mixed with a soft food to assist swallowing, the mixture must be used immediately and cannot be stored for later administration.

Disposal Guidance

When discarding unused or expired Dilzene, patients should consult a doctor or pharmacist for proper disposal instructions, as specific disposal procedures may vary based on local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dilzene found in:

A-Z Index: